FPF
VTGN icon

FNY Partners Fund’s VistaGen Therapeutics VTGN Stock Holding History

FNY Partners Fund’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-100
Closed -$3K – 481
2017
Q4 		$3K Buy
+100
New +$3.3K ﹤0.01% 383

Other funds holding VTGN

SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
II
Ibex Investors Denver, Colorado $194M AUM 23.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
LTFS
Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return
CA
Corrado Advisors Ramsey, New Jersey $217M AUM 26.96% 1-Year Est. Return
DADC
D.A. Davidson & Co Great Falls, Montana $18.1B AUM 24.63% 1-Year Est. Return
Parallax Volatility Advisers
Parallax Volatility Advisers San Francisco, California $58.9B AUM 51.73% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

FNY Partners Fund's VTGN Position: Q1 2018 in Review

FNY Partners Fund sold out of VistaGen Therapeutics (VTGN) in Q1 2018, closing a stake of 100 shares — an estimated $3K sold.

FNY Partners Fund first reported a position in VTGN in Q4 2017 and held it in 1 quarter. The position peaked at $3K in Q4 2017. 20 funds tracked by Wall St. Rank hold VTGN as of Q1 2018.

  • FNY Partners Fund reported no remaining VistaGen Therapeutics position as of Q1 2018 after selling out during the quarter.
  • FNY Partners Fund sold 100 VistaGen Therapeutics shares in Q1 2018, an estimated $3K.
  • FNY Partners Fund first reported a position in VistaGen Therapeutics in Q4 2017 and held it in 1 quarter.
  • FNY Partners Fund's VistaGen Therapeutics position peaked at $3K in Q4 2017.
  • 20 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q1 2018.

Based on FNY Partners Fund's 13F filing for Q1 2018, filed 18 Apr 2018.